Novartis AG ADR (NVS)vsOpko Health Inc (OPK)
NVS
Novartis AG ADR
$158.83
-0.24%
HEALTHCARE · Cap: $290.96B
OPK
Opko Health Inc
$1.37
-17.27%
HEALTHCARE · Cap: $913.66M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 9656% more annual revenue ($56.69B vs $581.12M). NVS leads profitability with a 22.5% profit margin vs -36.6%. NVS appears more attractively valued with a PEG of 4.15. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
OPK
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-68.7%
Fair Value
$92.54
Current Price
$158.83
$66.29 premium
Intrinsic value data unavailable for OPK.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 31.8%
Keeps 23 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Reasonable price relative to book value
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Smaller company, higher risk/reward
Weak financial health signals
Expensive relative to growth rate
ROE of -17.7% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 31.8%.
Bull Case : OPK
The strongest argument for OPK centers on Price/Book.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : OPK
The primary concerns for OPK are Market Cap, Piotroski F-Score, PEG Ratio.
Key Dynamics to Monitor
NVS profiles as a value stock while OPK is a turnaround play — different risk/reward profiles.
OPK carries more volatility with a beta of 1.48 — expect wider price swings.
NVS is growing revenue faster at 0.8% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 31/100), backed by strong 22.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Opko Health Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
OPKO Health, Inc., a healthcare company, is engaged in the pharmaceutical and diagnostic businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company is headquartered in Miami, Florida.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?